Other Guidelines | Page 5 | European Cystic Fibrosis Society (ECFS)

Drug-Induced Liver Injury from Elexacaftor/Ivacaftor/Tezacaftor

Urinary tract infections in cystic fibrosis patients

Experience of COVID-19 during the first wave in children with cystic fibrosis worldwide.

Utilization of Electronic Patient-Reported Outcome Measures in Cystic Fibrosis Research

Opioid Pain Management Among Adults with CF: Survey Results

How frequent is the condition of overweight among patients with cystic fibrosis in Italy?

Use of LCI to monitor CFTR Modulator effect in people with CF

How does the cystic fibrosis drug ivacaftor move in the body during pregnancy and breastfeeding?

New drug for cystic fibrosis does not significantly interfere with another drug that prevents organ rejection

Generalized accelerated recurrence time model for multivariate recurrent event data with missing event type

first
previous
1
2
3
4
5
6
7
8
9
…
next
last